Want to see AU:ENP full AI Analyst Report?
Top Page
Tryptamine Therapeutics
(Sydney:ENP)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.03
▼(-25.00% Downside)
Action:Reiterated
Date:01/20/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and significant cash burn implying continued funding needs), partially offset by a debt-free balance sheet and positive equity. Technical indicators are neutral-to-soft, and valuation is unattractive/unclear due to negative earnings and no dividend support.
Positive Factors
Low Leverage / Debt-Free Balance Sheet
Zero reported debt in FY2025–FY2024 is a durable financial strength for a pre-commercial biotech. It reduces insolvency and covenant risk, preserves strategic optionality for R&D funding, and improves the company's ability to negotiate partnerships or raise equity on less onerous terms over the next 2–6 months.
Negative Factors
No Revenue / Pre-commercial Status
Zero revenue over consecutive years is a structural weakness: it means products are not yet commercialized, operations are not revenue-backed, and there is no proof of market adoption or scalable margins. This keeps earnings dependent on future trial outcomes and external funding over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Debt-Free Balance Sheet
Zero reported debt in FY2025–FY2024 is a durable financial strength for a pre-commercial biotech. It reduces insolvency and covenant risk, preserves strategic optionality for R&D funding, and improves the company's ability to negotiate partnerships or raise equity on less onerous terms over the next 2–6 months.
Read all positive factors
Tryptamine Therapeutics (ENP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$66.98M
Dividend YieldN/A
Average Volume (3M)1.87M
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS Growth29.55%
CountryAU
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,633,593,800
10 Day Avg. Volume2,098,027
30 Day Avg. Volume1,868,201
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)6.82
Price to Sales (P/S)0.00
P/FCF Ratio-14.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tryptamine Therapeutics Business Overview & Revenue Model
Company Description
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical co...
How the Company Makes Money
null...
Tryptamine Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
26
Negative
| Breakdown | Jun 2026 | Aug 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 618.57K | 99.73K |
| Gross Profit | -27.34K | -54.34K | -6.77K | 618.57K | 99.73K |
| EBITDA | -6.74M | -5.27M | -6.70M | -5.10M | -8.27M |
| Net Income | -4.87M | -5.33M | -6.14M | -7.13M | -10.08M |
Balance Sheet | |||||
| Total Assets | 8.38M | 6.66M | 7.45M | 5.88M | 13.61M |
| Cash, Cash Equivalents and Short-Term Investments | 5.58M | 3.03M | 5.37M | 1.64M | 4.85M |
| Total Debt | 0.00 | 0.00 | 0.00 | 1.53M | 3.74M |
| Total Liabilities | 1.02M | 699.17K | 1.83M | 1.75M | 4.81M |
| Stockholders Equity | 7.36M | 5.96M | 5.62M | 4.13M | 8.81M |
Cash Flow | |||||
| Free Cash Flow | -3.41M | -7.90M | -6.00M | -4.03M | -9.72M |
| Operating Cash Flow | -3.41M | -7.77M | -6.00M | -4.03M | -8.59M |
| Investing Cash Flow | -10.41K | -133.40K | 1.68M | -9.08K | -1.24M |
| Financing Cash Flow | 5.97M | 5.60M | 9.27M | 2.39M | 1.95M |
Tryptamine Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.58B | 128.43 | 6.03% | 0.00% | -68.00% | -86.31% | |
54 Neutral | AU$66.73M | -7.78 | -18.71% | ― | ― | 21.23% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$198.79M | -11.04 | -103.42% | ― | ― | 5.88% | |
46 Neutral | AU$23.77M | -4.39 | -30.02% | ― | ― | -10.32% | |
45 Neutral | AU$66.98M | -17.83 | -63.60% | ― | ― | 29.55% |
* Healthcare Sector Average
AU:ENP
Tryptamine Therapeutics
0.04
<0.01
28.13%
AU:ATX
Amplia Therapeutics
0.13
-0.02
-16.13%
AU:ACW
Actinogen Medical
0.05
0.03
96.30%
AU:NEU
Neuren Pharmaceuticals Limited
20.33
-0.47
-2.26%
AU:ZLD
Zelira Therapeutics
0.50
0.13
33.33%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.06
-0.11
-64.12%
Tryptamine Therapeutics Corporate Events
Entropy Neurodynamics strengthens governance with new joint company secretary
Jul 24, 2026
Entropy Neurodynamics has appointed Meghna Piplani as Joint Company Secretary, effective 24 July 2026, where she will serve alongside existing secretary Hamish George. Piplani, a governance specialist at healthcare-focused advisory firm Bio101, br...
Entropy Neurodynamics Secures First Clinical Validation for IV Psilocin Platform
Jul 21, 2026
Entropy Neurodynamics reported a pivotal quarter, highlighting completion of cohort one dosing in its Phase 2 TRP-8803 trial for treatment-resistant Binge Eating Disorder and subsequent topline data showing 50% clinical remission and a 100% clinic...
Entropy Neurodynamics Posts Breakthrough Phase 2 Results for IV Psilocin in Binge Eating Disorder
Jul 6, 2026
Entropy Neurodynamics has reported topline Phase 2 Cohort 1 data for TRP-8803, an IV-infused psilocin therapy in treatment-resistant binge eating disorder. The precision-controlled psychedelic platform is intended to offer scalable, reproducible t...
Entropy Neurodynamics Halts Trading Pending Binge Eating Study Data
Jul 2, 2026
Entropy Neurodynamics Ltd has requested and received a trading halt on its ordinary shares from the Australian Securities Exchange, effective from 3 July 2026. The halt will remain in place until either the commencement of normal trading on 7 July...
Entropy Neurodynamics Seeks ASX Quotation for Large Option Class
Jun 26, 2026
Entropy Neurodynamics Limited has applied to the Australian Securities Exchange for the quotation of a previously unquoted class of options, designated ENPAD, without issuing any new securities under this application. The options, which total 300,...
Entropy Neurodynamics reveals concentrated ownership of 2027 listed options
Jun 26, 2026
Entropy Neurodynamics has released a top holders report for its listed options ENPOAWC26, priced at $0.027 and expiring on 29 May 2027, highlighting the concentration of ownership among major investors. The largest option holder is William James G...
Entropy Neurodynamics Plans Targeted ASX Options Issue
Jun 25, 2026
Entropy Neurodynamics Limited has lodged details of a proposed non pro rata offer of options under a disclosure document, seeking ASX quotation for the securities once issued. The company plans to issue up to 1,000 ENPAD options, expiring 29 May 2...
Entropy Neurodynamics launches tightly targeted options offer to support secondary trading
Jun 25, 2026
Entropy Neurodynamics Limited has issued a prospectus for an offer of up to 1,000 new options at an issue price of A$0.027 per option, each exercisable at the same price and expiring on 29 May 2027, with each option converting into one fully paid ...
Entropy Neurodynamics to List 49.9 Million Additional Shares on ASX
May 29, 2026
Entropy Neurodynamics Limited has lodged an application with the ASX for quotation of 49,873,318 ordinary fully paid shares under the code ENP. The securities are scheduled to be quoted from 29 May 2026, reflecting a transition of previously restr...
Entropy Neurodynamics to Release Escrowed Shares and Options, Boosting Liquidity
May 22, 2026
Entropy Neurodynamics Limited, a clinical-stage biotechnology company developing psilocin-based psychedelic therapies, is advancing its lead IV psilocin program TRP-8803 to address limitations of oral psilocybin and leverage positive Phase 2a data...
Entropy Neurodynamics Showcases TRP-8803 Platform at Australian Microcap Conference
May 10, 2026
Entropy Neurodynamics Limited has announced that its Managing Director and CEO, Jason Carroll, will present at the 15th Annual Australian Microcap Investment Conference in Sydney, highlighting the company’s proprietary TRP-8803 intravenous p...
Entropy Neurodynamics Files New U.S. Patent to Bolster IBS Psychedelic Therapy Program
May 5, 2026
Entropy Neurodynamics has filed a new U.S. provisional patent application covering psychedelic-assisted therapies for disorders of gut-brain interaction, expanding on its existing international and Australian IP for precision-controlled psilocybin...
Entropy Neurodynamics posts breakthrough 75% response in treatment-resistant IBS trial
May 3, 2026
Entropy Neurodynamics reported breakthrough Phase 2a data showing its oral psilocybin candidate TRP-8802 achieved a 75% response rate in 12 patients with treatment-resistant irritable bowel syndrome, far exceeding the 17–44% response seen wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.